logo
Trying to find its footing, Portillo's takes breakfast for a test run

Trying to find its footing, Portillo's takes breakfast for a test run

Chicago Tribune11-04-2025

Ice cream for breakfast? In Chicago, it's more like an Italian Beef.
Oak Brook-based hot dog giant Portillo's is trying out a breakfast menu for the first time in its 62 years, the company announced Friday. The trial menu — which will be available daily at five Chicago-area restaurants starting April 15 — comes as the homegrown chain has struggled, at times, to find its footing amidst ambitious national expansion plans.
Other than the Italian beef, the company's breakfast offerings are comparatively traditional, with more subtle nods to the company's heritage.
A Polish sausage, egg and cheese and a pepper, egg and cheese both come with Giardiniera sauce. Also on tap is coffee courtesy of Metropolis, including a chocolate cake iced coffee inspired by the Portillo's chocolate cake shake. A chocolate cake doughnut, topped with Portillo's chocolate cake frosting, was borne of a collaboration with Stan's Donuts.
Founded in a Villa Park parking lot in 1963, Portillo's was family-owned until 2014, when founder Dick Portillo sold the company to Boston-based private equity firm Berkshire Partners. Berkshire, in turn, took the hot dog empire public in 2021. Since then, Portillo's has announced ambitious plans to grow itself from a local chain to a truly national one, with plans to add hundreds of restaurants to its current fleet of more than 90 outposts over the next two decades.
But the company has struggled to find its footing at times, facing investor activism, labor disputes and complaints from some patrons that the food isn't quite as good as it used to be. Its stock price, which hit a high of more than $50 shortly after its IPO, closed around $11 on Thursday.
David Henkes, senior principal at Chicago-based food service research firm Technomic, said he isn't surprised that Portillo's would try out breakfast.
'It's all in search of growth right now,' said Henkes, speaking before the details of Portillo's dayside offerings became available.
Breakfast will be available at the company's 520 W. Taylor St. restaurant in Chicago as well as one location each in suburban Elmhurst, Tinley Park, Shorewood and Niles.
Breakfast will be served at least through the summer, though the trial could expand to other restaurants or into the fall. Breakfast hours will be from 6:30 a.m. to 10:30 a.m.
'Chicago has been asking for Portillo's breakfast for years, and we're thrilled to deliver our unique take on morning classics,' the company's vice president of strategy and culinary, Garrett Kern, said in a statement.
For $7.99, customers can get a meal deal that comes with a breakfast sandwich, hash brown bites and a small coffee. Individual breakfast sandwiches, including a bacon, egg and cheese on a croissant, go from $4.99 to $5.29. Chocolate cake doughnuts will run you $2.79 apiece and $24.99 for a dozen.
The breakfast move comes after the company's activist investor, Engaged Capital, launched a proxy fight by nominating two independent candidates to the company's board last month. At the time, Portillo's said in a statement that it 'values the perspectives of all of its shareholders' and had 'held numerous meetings with representatives of Engaged Capital to better understand their views and recommendations.'
Sources familiar with conversations between Portillo's and Engaged suggested the activist thought offering breakfast could help drive in-store traffic, provided the company executes the attempt well.
Portillo's revenue increased 4.5% in 2024, the company said in a fourth-quarter earnings release earlier this year. But that growth primarily came from new restaurant openings — same-store sales, which Engaged hopes to boost, declined 0.6% during the same period.
Portillo's will announce its first quarter earnings at the beginning of May.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Signs removed at family business pizza takeaway as building listed for sale
Signs removed at family business pizza takeaway as building listed for sale

Yahoo

time17 minutes ago

  • Yahoo

Signs removed at family business pizza takeaway as building listed for sale

SIGNS have been removed from a family business pizza takeaway in Warrington, as the building is listed for sale. Signage has been removed in recent weeks on the Don Quattro building, located at Fearnhead Cross on Insall Road. The business is a sister venue for the ever-popular Donatello Italian restaurant, which opened on Orford Lane in 1996. Don Quattro opened in spring 2022, due to the success of Donatello takeaways during the Covid pandemic, and it was hoped that this would be the first of a few takeaway venues in the town. However, the 982 square-foot building has been listed for sale with estate agents Morgan Williams Commercial, with offers in the region of £120,000 considered. The listing states: 'We are delighted to bring to market this wonderful leasehold business for sale. 'The property is a prominent detached former pizza takeaway, suitable for similar retail trades. 'Inside, the unit is fully refurbished and contains high-quality equipment, which is available for purchase. Signs have been removed from the Don Quattro pizza takeaway building in Fearnhead 'The fixtures and fittings list is extensive, and it includes items such as an artisan rotating base pizza oven, full extraction system, and CCTC. 'The property benefits from its own private car park, which can hold approximately seven cars at one time. 'Kitchen and prep areas are well stocked with equipment that forms part of the sale. 'The property is currently trading by our clients as an established pizzeria business, and it will be ideal for a similar use or other takeaway food businesses. 'Our client is the current owner of the business, and they are looking for offers in the region of £120,000 to take full ownership of the lease and fixtures and fittings. 'The purchaser will be assigned the existing, long-term FRI lease direct from the landlord, whereby the current rent passing is £30,000 per annum. 'The property benefits from planning consent under application number 2021/39225, which permits takeaway trade between the hours of 5pm to 11pm, Monday to Friday, midday to 11.30pm on Saturdays, and midday to 11pm on Sundays and bank holidays.'

SNP ferry scheme suffers fresh blow after rain causes ship to flood
SNP ferry scheme suffers fresh blow after rain causes ship to flood

Yahoo

time20 minutes ago

  • Yahoo

SNP ferry scheme suffers fresh blow after rain causes ship to flood

The SNP's disastrous ferry-replacement programme suffered another blow after a vessel that was already six years behind schedule flooded. The MV Glen Rosa, which is running £100m over budget, filled with rainwater after the funnels were removed at the nationalised Ferguson Marine shipyard in Port Glasgow. It is understood that engineers removed the smokestacks to allow the installation of the ferry's engines, with one of the tarpaulins used to cover the holes created coming loose. Sudden heavy rainfall subsequently saw water pour into the ship, under construction for ferry operator CalMac, before the exposed exhaust vent could be covered again. Hugh McKenzie, the operations manager at Ferguson Marine, said the Glen Rosa had 'experienced some internal water ingress' during heavy rainfall at the end of last month. He said: 'The affected area has been dried out and thoroughly inspected. No damage or lasting impact was identified, and the incident has not resulted in any further issues.' Before the flooding, Mr McKenzie said that the removal of the funnels was a 'critical step' in the installation of the ferry's main and auxiliary engines, and had been 'meticulously planned for as part of the build schedule'. The latest setback comes less than a month after Ferguson Marine said the Glen Rosa would miss its much-revised delivery date of September by up to nine months. The shipbuilder said it now expected the vessel to be 'substantially complete' only in the first quarter of next year, with delivery between April and June. Ferguson Marine also revealed that the cost of the Glen Rosa had jumped by a further £35m, meaning that it and the Glen Sannox will come in at more than £460m including written-off loans – more than four and a half times the original contract price. Taking into account the £252m spent on keeping ageing vessels in service to cover for the delays, the overall bill is more than £700m, CalMac has stated. Both new vessels were ordered for CalMac's busiest route, linking the Isle of Arran with the Scottish mainland. Ferguson Marine is desperate for work after Caledonian Maritime, which procures vessels for CalMac and reports to Scotland's transport minister, awarded a deal for seven smaller electric ferries to a Polish firm. Despite the failures and upheaval, the SNP last month awarded CalMac a £3.9bn deal to run ferries to the Hebrides for a further decade without the contract being put out to tender. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.

Hologic Climbs 13% in a Month: How Should You Play the Stock?
Hologic Climbs 13% in a Month: How Should You Play the Stock?

Yahoo

time44 minutes ago

  • Yahoo

Hologic Climbs 13% in a Month: How Should You Play the Stock?

After lagging for months, Hologic HOLX has picked up momentum in recent weeks. Shares of the Marlborough, MA-based company have climbed 13.3% over the past month, higher than the industry and the broader Medical sector's gains of 2.4% and 3.4%, respectively. The current price is now 23.9% above the 52-week low of $51.90, boosted in part by reports that Hologic declined a private takeover bid from TPG and Blackstone. HOLX has also managed to outperform two of its key competitors — Exact Sciences EXAS and Becton, Dickinson and Company BDX, or BD, in the same time frame. Image Source: Zacks Investment Research Investor sentiment was already subdued after the release of the company's fiscal 2025 second-quarter earnings in early May. Hologic met adjusted EPS expectations with a modest revenue beat but revised its annual outlook due to the growing tariff impact from China and Costa Rica, funding cuts affecting the Africa business, and a soft capital equipment market. In contrast, Exact Sciences anticipates 'little to no tariff impact' due to all domestic operations, while BD expects $90 million in tariff expenses for fiscal 2025, mostly from China imports. That said, let's explore what might be driving Hologic's recent rally. On May 27, HOLX shares rose nearly 15% following a report from the Financial Times that the company turned down a non-binding offer from private equity (PE) firms TPG and Blackstone. The deal was valued at up to $16.7 billion, including debt. These firms, known for their solid history of healthcare investments, teamed up last year to explore a potential acquisition of Bausch + Lomb, which eventually did not happen. The proposed takeover bid of Hologic would have been one of the largest leveraged buyouts of the year, valuing the company's shares between $70 and $72 — roughly a 30% premium to the May 23 closing price of $54.28. The report also stated that there is a possibility the deal discussions might resume, according to people with knowledge of the matter. Hologic has attracted buyers' attention for a while now. Of late, the take-private activities by PE firms have seen a sharp increase, such as Sycamore Partners' $24 billion deal for Walgreens Boots Alliance, Thoma Bravo's $10.6 billion acquisition of Boeing's software unit, and 3G Capital's $10.5 billion deal for Skechers. Nonetheless, the high premium in the offer signals strong confidence in Hologic's growth potential. The company presented new data showing the significant clinical impact of the Breast Cancer Index ('BCI') test at the 2025 American Society of Clinical Oncology Annual Meeting held on June 2. The molecular, gene expression-based test from Hologic's subsidiary, Biotheranostics, has been a key growth driver in the molecular diagnostics business over the past few quarters. The latest data from the prospective, multi-center BCI Registry Study highlights how this genomic test plays a critical role in guiding extended endocrine therapy decisions for women with early-stage, hormone receptor-positive (HR+) breast cancer. With more than 2,800 patients involved, the study found that BCI testing led to a change in treatment recommendations for about four in 10 cases. Additionally, physicians' confidence in their treatment recommendations got a boost, while patients felt comfortable in their decisions, citing fewer concerns about cost, drug safety and preference related to extended endocrine therapy benefits. Hologic looks attractive from a valuation standpoint. The stock has been trading at a price-to-sales (P/S) of 3.40X over the past five years compared to its median of 4.33X and the industry average of 4.16X. It has a Value Score of B at present. Image Source: Zacks Investment Research Meanwhile, both Exact Sciences and BD are trading at a premium to their industry average, with P/S of 3.16X and 2.20X respectively. Molecular Diagnostics assays are likely to continue to be the principal revenue-generating component in the Diagnostics division. As Hologic drives awareness and reimbursement in the highly unpenetrated U.S. vaginitis market, the BV CV/TV assay is poised to see a strong uptake. Aligning with its long-term revenue diversification strategy, the company's Breast Health service revenues are now larger and growing more steadily than the gantry business. The 2024 acquisition of Endomagnetics boosted the Interventional Breast portfolio with market-leading product lines and strong R&D capabilities for further portfolio expansion. The upcoming launch of innovations like the Envision Mammography Platform is likely to gain a favorable reception. In Surgical, Myosure's strong international growth points to the high demand for minimally invasive options for treating uterine polyps and fibroids. Hologic continues to expand this division both organically and through acquisitions such as Gynsesonics, leveraging its established sales channel. Further, the company is building capabilities to grow internationally on a consistent basis by going directly into more geographies and businesses. A consistently strong profitability has contributed to a fortress balance sheet over time, allowing Hologic to execute on both tuck-in M&A and share repurchases. Based on short-term price targets offered by 15 analysts, the Zacks average price target is $68.13 per share. The average suggests a potential 8.02% upside from last Friday's closing price. Image Source: Zacks Investment Research Hologic has some promising catalysts for long-term expansion, supported by an attractive valuation relative to its industry. However, despite outperforming peers over the past month, the Zacks Rank #3 (Hold) stock is navigating a turbulent macroeconomic landscape, which is expected to weigh on its financial performance in the near term. Hence, those eyeing HOLX may find it wise to wait for a better entry point, while current shareholders should retain their position. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store